Summit Therapeutics Inc (SMMT) - News Archive

As the landscape of cancer therapy continues to evolve, recent advancements in bispecific antibody treatments are capturing the spotlight. One such innovation is ivonescimab, an investigational antibody that has demonst...

Summit Therapeutics Inc. (NASDAQ: SMMT) has announced a significant advancement in its clinical portfolio with the launch of the global Phase III HARMONi-GI3 trial. This study will investigate the efficacy of the invest...

The treatment landscape for squamous non-small cell lung cancer (squamous NSCLC) has witnessed significant advancements with the introduction of novel therapeutic agents. The recent Phase III HARMONi-6 study conducted b...

In recent news, the Pomerantz Law Firm has initiated an investigation into Summit Therapeutics Inc., a biotechnology firm publicly traded on the NASDAQ under the ticker symbol SMMT. This investigative action raises impo...

Title : Emerging Trends in Lung Cancer Treatment: Phase III HARMONi Trial Reveals Promising Results for Ivonescimab Plus Chemotherapy:In a significant advancement in oncology, Summit Therapeutics Inc. (NASDAQ: SMMT) has...

Advancements in Lung Cancer Treatment: Summit Therapeutics Set to Discuss Phase III Ivonescimab Data at WCLC 2025Summit Therapeutics Inc. (NASDAQ: SMMT), a company known for its innovative approach to drug development,...

This article examines the ongoing investigation led by Pomerantz Law Firm into claims on behalf of investors of Summit Therapeutics Inc. (NASDAQ: SMMT). As the company faces scrutiny, the implications of investor confid...

The advancement of biotherapeutics has significantly altered the landscape of oncological therapies, particularly in the realm of immune checkpoint inhibitors. This article examines intravenous ivonescimab, a potential...

Summit Therapeutics Inc. has made significant strides in oncology research with the completion of patient enrollment in the Phase III HARMONi clinical trial. This study is pivotal in evaluating the efficacy of ivonescim...

In a significant stride towards advancing cancer treatment, Summit Therapeutics Inc. (NASDAQ: SMMT) has announced the successful completion of patient enrollment in its pivotal Phase III HARMONi clinical trial. This mul...

Breaking Ground in Oncology: Promising Developments of Ivonescimab at ESMO 2024The battle against cancer continues to evolve with innovative therapies on the horizon, contributing to an increasingly promising future for...

: Recent advancements in immunotherapy have become pivotal in the treatment landscape for non-small cell lung cancer (NSCLC), particularly in patients presenting with programmed death-ligand 1 (PD-L1) positivity. Summit...

As the landscape of oncology advances through relentless research and innovative treatments, Summit Therapeutics Inc. (NASDAQ: SMMT) is making a significant mark with its promising investigational bispecific antibody, i...

The landscape of cancer therapy continues to evolve with the emergence of advanced therapeutics. A notable example is ivonescimab, a potential first-in-class PD-1/VEGF bispecific antibody. Summit Therapeutics Inc. and T...

Investors in Summit Therapeutics Inc have experienced a frustrating year, with the company s shares failing to meet expectations. This article aims to provide an analysis of the recent developments surrounding Summit Th...

Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit or the Company) announced that on May 24, 2024, their partner Akeso Inc. (HKEX Code: 9926.HK) received marketing authorization in China for ivonescimab (SMT112) in combina...

In a recent Phase III clinical trial, Summit Therapeutics Inc. announced promising results for their investigational drug, ivonescimab, in the treatment of non-small cell lung cancer (NSCLC) patients with positive PD-L1...

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024Summit Therapeutics Inc. (NASDAQ: SMMT) has presented promising data for their inve...

Summit Therapeutics Inc. (NASDAQ: SMMT) recently announced the forthcoming presentation of data on their novel bispecific antibody, ivonescimab, at the 2024 European Lung Cancer Congress (ELCC 2024). The data showcases...

Summit Therapeutics, a ground-breaking, revolutionary healthcare company renowned for its pioneering clinical programmes aimed to bring new treatment options for patients suffering from infectious diseases, recently pro...